XML 36 R22.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUE AND SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2025
REVENUE AND SEGMENT INFORMATION  
Schedule of disaggregation of revenue

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended September 30, 2025:

Distributors/

    

Direct

    

Strategic Partners

    

Total

(amounts, in thousands)

Revenue:

 

  

 

  

 

  

United States

$

28

$

$

28

Germany

 

2,899

 

 

2,899

All other countries

 

2,246

 

4,312

 

6,558

Revenue

$

5,173

$

4,312

$

9,485

The following table disaggregates the Company’s revenue by customer type and geographic area for the three months ended September 30, 2024:

Distributors/

    

Direct

    

Strategic Partners

    

Total

(amounts, in thousands)

Revenue:

  

  

  

United States

$

21

$

$

21

Germany

 

3,181

 

 

3,181

All other countries

 

1,937

 

3,474

 

5,411

Revenue

$

5,139

$

3,474

$

8,613

The following table disaggregates the Company’s revenue by customer type and geographic area for the nine months ended September 30, 2025:

Distributors/

    

Direct

    

Strategic Partners

    

Total

(amounts, in thousands)

Revenue:

 

  

 

  

 

  

United States

$

152

$

$

152

Germany

 

9,050

9,050

All other countries

 

6,344

12,283

18,627

Revenue

$

15,546

$

12,283

$

27,829

The following table disaggregates the Company’s revenue by customer type and geographic area for the nine months ended September 30, 2024:

Distributors/

    

Direct

    

Strategic Partners

    

Total

(amounts, in thousands)

Revenue:

 

  

 

  

 

  

United States

$

63

$

36

$

99

Germany

 

9,497

9,497

All other countries

 

5,362

11,486

16,848

Revenue

$

14,922

$

11,522

$

26,444

Schedule of receivables and contract liabilities from contracts with customers

    

September 30, 2025

    

December 31, 2024

    

    (amounts in thousands)

Contract receivables

$

5,997

$

4,427

Contract liabilities

$

403

$

596

Schedule of segment information

    

Three Months Ended

    

Nine Months Ended

 

September 30, 

September 30, 

 

    

2025

    

2024

    

2025

    

2024

 

    

(amounts, in thousands)

Revenue

$

9,485

$

8,613

$

27,829

$

26,444

Gross profit

$

6,666

$

5,256

$

19,687

$

18,632

Gross margin

 

70

%

 

61

%

 

71

%

 

70

%

Total operating expenses

$

9,528

$

10,086

$

30,051

$

31,689

Loss from operations

$

(2,862)

$

(4,830)

$

(10,364)

$

(13,057)

EBITDA and Adjusted EBITDA (both non-GAAP measures):

 

 

 

 

Net loss

$

(3,170)

$

(2,768)

$

(2,701)

$

(13,152)

Interest expense, net

 

645

 

588

 

1,866

 

775

Benefit from income taxes

 

(401)

 

 

(401)

 

Depreciation and amortization expense

 

364

 

383

 

1,137

 

1,181

Loss before interest expense, income taxes, depreciation and amortization (“EBITDA”), a non-GAAP measure

 

(2,562)

 

(1,797)

 

(99)

 

(11,196)

Stock-based compensation

 

488

 

891

 

1,879

 

2,840

Loss (gain) on foreign currency transactions

64

 

(2,650)

(9,128)

 

(680)

Adjusted EBITDA, a non-GAAP measure

$

(2,010)

$

(3,556)

$

(7,348)

$

(9,036)

Adjusted net loss, a non-GAAP measure:

 

 

 

 

Net loss

$

(3,170)

$

(2,768)

$

(2,701)

$

(13,152)

Stock-based compensation

 

488

 

891

 

1,879

 

2,840

Loss (gain) on foreign currency transactions

64

(2,650)

(9,128)

(680)

Adjusted net loss, a non-GAAP measure

$

(2,618)

$

(4,527)

$

(9,950)

$

(10,992)

Total cash used in operating and investing activities

$

(2,522)

$

(2,762)

$

(7,676)

$

(12,632)

    

September 30, 2025

    

December 31, 2024

(amounts, in thousands)

Total assets

$

45,750

$

47,372

    

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2025

    

2024

    

2025

    

2024

(amounts, in thousands)

Research and development:

 

  

 

  

Clinical expenses

$

719

$

936

$

2,510

$

3,499

Other research and development expenses

 

199

 

890

 

1,332

 

2,093

Total research and development

$

918

$

1,826

$

3,842

$

5,592

Selling, general and administrative

 

  

 

 

  

 

  

Royalty expense

$

285

$

354

$

826

$

1,594

Stock-based compensation

 

376

 

843

 

1,435

 

2,792

Legal, financial and consulting

 

1,061

 

824

 

3,063

 

2,325

Other general and administrative

 

6,888

 

6,239

 

20,885

 

19,386

Total selling, general and administrative

$

8,610

$

8,260

$

26,209

$

26,097